Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Celera to Acquire Minority Interest in HuBit Genomix
April 2, 2001
- Radicut, Herceptin, Zyvox Approved by CDFS
April 2, 2001
- DIAGNOSTIC NEWS IN BRIEF
April 2, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- DPJ Starts Discussions on Healthcare Reform
March 26, 2001
- OTC NEWS IN BRIEF
March 26, 2001
- Medical Institution Information System to Go into Operation in Osaka
March 26, 2001
- Kemporen Members' Ordinary Loss to Increase to \490.4 Bil.
March 26, 2001
- PMSB to Publish Criteria for Disclosure or Non-disclosure of Information
March 26, 2001
- Aiming at \30 Billion Sales in 2005: Mr Strenger of Aventis Behring
March 26, 2001
- More Patents Exported than Imported in Pharmaceutical Field
March 26, 2001
- Roche's Herceptin Marks Step toward Tailor-made Medicine
March 26, 2001
- Korosho Supplies Anti-AIDS Drugs Unapproved in Japan to 393 Patients
March 26, 2001
- Kissei, Daiichi to Codevelop Agent for Dysuria
March 26, 2001
- BULLETIN
March 26, 2001
- Kissei to Market Sumitomo's Falecalcitriol
March 26, 2001
- Government Council Proposes Lump-sum Payment by Type, Severity of Illness
March 26, 2001
- Pharmacia's Solu-Medrol Approved for Bronchial Asthma
March 26, 2001
- HPB Creates Study Team on Insurance Healthcare Information Systems
March 26, 2001
- JPMA to Create Consortium for Analysis of Protein Structure in FY2001
March 26, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…